Pancreatic cancer (PC) remains one of the deadliest malignancies in the United States. According to recent cancer statistics, it will be overtaking the position of breast cancer as the third leading cause of cancer-related death by the end of this year ([@bib38]). Nearly 53 070 people are expected to be diagnosed with PC and ∼41 780 will succumb to its severity. The median survival of patients still remains 5--8 months and the 5 year survival rate is 7% ([@bib38]). This grim scenario largely reflects the inefficacy of current drug regimens against the advanced disease. Therefore, it is highly imperative that we understand causes of therapeutic failure at the molecular level and develop novel, mechanism-based therapies for effective PC treatment.

Gemcitabine (2′, 2′-difluoro-2′-deoxycytidine) remains the drug of choice that is used either alone or in combination with other drugs depending on the health status of PC patients ([@bib45]; [@bib24]). However, in either case, it has not resulted in marked lift in patient\'s survival likely due to the presence of innate or acquired chemoresistance mechanisms ([@bib37]; [@bib28]; [@bib21]). To overcome existing limitations in PC treatment, newer mechanism-based approaches have been tested that target intrinsic or acquired survival mechanisms or improve drug accumulation at the tumour site ([@bib23]; [@bib30]; [@bib20]; [@bib31]; [@bib36]). However, some of these approaches have entirely failed ([@bib1]), whereas others have only resulted in a modest increase in patient\'s survival ([@bib27]; [@bib45]).

Extracellular vesicles (EVs) shed by tumour cells serve as important mediators of intercellular communication and thus influence the process of carcinogenesis in various ways ([@bib16]; [@bib34]; [@bib19]; [@bib33]). Extracellular vesicle are heterogeneous in size, molecular contents as well as their cellular origin ([@bib11]; [@bib32]). Exosomes are generally the most abundant type of EVs that range in size from 30 to 150 nm ([@bib34]; [@bib32]). They are of endosomal origin and act as efficient carriers of RNAs (including miRNAs), proteins and other bioactive molecules ([@bib16]; [@bib34]). Recently, pancreatic tumour cells were reported to shed exosomes expressing glypican-1 as a surface marker that were detected in serum samples of PC patients ([@bib26]). In another report, pancreatic tumour-derived exosomes were shown to promote liver metastasis via their induction of pre-metastatic niche formation ([@bib12]). In a subsequent study, proteomic profiling of pancreatic tumour-derived exosomes revealed the presence of distinct integrin isoforms on the surface of exosomes that were involved in organ-specific homing of metastatic tumour cells ([@bib18]).

The present study explored a novel exosome-mediated mechanism for the acquired chemoresistance of PC. We demonstrate that conditioned media (CM) of gemcitabine-treated PC cells (Gem-CM) and specifically its EV fraction (Gem-EV) confer chemoresistance to PC cells. Moreover, we show that exosomes are the major active subtype of Gem-EV that contribute to acquired chemoresistance by increasing the levels of superoxide dismutase 2 (SOD2) and catalase (CAT; ROS-detoxifying enzymes) likely through lateral transfer of their transcripts and through miR-155-mediated downregulation of gemcitabine-metabolising enzyme, deoxycytidine kinase (DCK).

Materials and methods
=====================

Reagents, plasmids and antibodies
---------------------------------

The following reagents were used in the study: Roswell Park Memorial Institute Medium-1660, Dulbecco\'s modified Eagle medium, phosphate buffer saline (PBS), penicillin (10 000 U ml^−1^) streptomycin (10 000 *μ*g ml^−1^), fetal bovine serum (FBS) and trypsin-EDTA were from Hyclone Laboratory (Logan, UT, USA); exosome-free FBS was from System BioScience (Palo Alto, CA, USA); sodium dodecyl sulphate-polyacrylamyde gel electrophoresis (SDS-PAGE) reagents and protein DC assay kit were purchased from Bio-Rad (Hercules, CA, USA); exosomes-anti-CD63 (10628D), total exosome RNA and protein isolation kit, and cDNA synthesis kit were from Invitrogen (Carlsbad, CA, USA); Taqman advanced miRNA cDNA synthesis kit and SYBR green/rox Q-PCR master mixes from Applied Biosystems (Carlsbad, CA, USA); Quickchange XL site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA); Dual-Luciferase assay kit from Promega (Madison, WI, USA); and inhibitors for SOD2 (diethyldithiocarbamate, DDC) and CAT (3-amino-1,2,4-triazole, AT) purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies targeting CD9 (ab2215), ARF6 (ab77581), thrombospondin (THBS; ab88529), C3b (ab11871) and DCK (ab151966) were procured from Abcam (Cambridge, MA, USA), whereas SOD2 (13194) and CAT (14097) from Cell Signaling Technology (Danvers, MA, USA) and *β*-actin from Sigma-Aldrich (St Louis, MO, USA); respective anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies were procured from Santa Cruz Biotechnology; WST-1 proliferation assay reagent from Roche (Indianapolis, IN, USA). Deoxycytidine kinase-overexpressing plasmid (pDONR223-DCK; plasmid number 23381) from William Hahn and David Root laboratory was procured from Addgene (Cambridge, MA, USA). Deoxycytidine kinase 3′-UTR region (Genecoepia, Rockville, MD, USA); gemcitabine (2′,2′ difluoro 2′-deoxycytidine) and *N*-acetyl-L-cysteine (NAC) were from Sigma-Aldrich; anti-miR-155 or miRNA inhibitor negative controls and 2′,7′-dichloro-fluorescin diacetate (DCFDA) were purchased from Sigma-Aldrich. ON-TARGETplus Human DCK siRNAs, Non-targeting Control siRNAs Pool and DharmaFECT transfection reagent were from Dharmacon (Lafayette, CO, USA).

Cell culture, treatment and transfection
----------------------------------------

MiaPaCa and Colo-357 cells were procured and maintained as described earlier ([@bib22]). Cell lines used in this study were authenticated by either in-house or commercial (Genetica DNA Laboratories, Burlington, NC, USA) short-tandem repeats genotyping. Cells were seeded in 96- or 6-well plates and treated with CM or soluble fraction (SF) or EVs fraction or subfraction of EVs (5 *μ*g ml^−1^) collected from vehicle or gemcitabine-treated cells for 12 h or additional 24--72 h and used for further functional assays and/or mechanistic assays as described in pertinent figure legends. To dissect the role of SOD2 and CAT, PC cells were pretreated with DDC (1.0 *μ*[M]{.smallcaps}) and AT (10 *μ*[M]{.smallcaps}) for 1 h and further treated with Veh-Exo or Gem-Exo alone or in combination. Pancreatic cancer cells were transiently transfected with anti-miR-155 or miRNA inhibitor negative controls (50 n[M]{.smallcaps}) using X-tremeGENE HP DNA transfection reagent for 24 h. For DCK overexpression, cells were transiently transfected with pDONR223-DCK construct (lacking 3′-UTR region) or control plasmid using X-tremeGENE HP DNA transfection reagent.

Collection and fractionation of condition media
-----------------------------------------------

Cells were treated with vehicle (PBS) or gemcitabine (10 *μ*[M]{.smallcaps}) for 8 h in regular media. Post treatment, cells were washed and cultured in exosome-free FBS-supplemented media for 48 h. Thereafter, CM was collected, centrifuged at 300 × g for 10 min to remove cell debris and designated as Veh-CM (from vehicle-treated cells) and Gem-CM (from gemcitabine-treated cells). Subsequently, Veh-CM and Gem-CM were subjected to ultracentrifugation (120 000 × g at 4 °C for 2 h) to collect respective SFs (Veh-SF and Gem-SF) and total EVs (Veh-EVs and Gem-EVs). Based on their size, EVs were further sub-fractioned by differential centrifugation into large (at 2000 × g for 30 min), medium (at 16 500 × g for 30 min) and small (at 120 000 × g for 2 h) EVs. Extracellular vesicles were washed and quantified using DC protein assay kit and used for subsequent analysis and PC cells treatment.

Size determination of EVs using dynamic light scattering
--------------------------------------------------------

To determine the size, freshly sub-fractionated EVs (0.5 *μ*g *μ*l^−1^) were diluted (1 : 1000) in deionised water and 10 spectra were recorded for each fraction from three biological replicates at 25 °C using DelsaMax Pro light scattering analyser (Backman Coulter Inc., Atlanta, GA, USA).

Cell viability assay
--------------------

Cells were seeded in 96-well plates (5 × 10^3^ cells per well), grown for 24 h and treated with CM or SF or different EVs in exosome-depleted media. After 12 h of pretreatment, cells were further treated with gemcitabine (0--80 *μ*[M]{.smallcaps}) for 72 h. In other experiments, PC cells were treated with SOD2/CAT inhibitors, NAC, DCK overexpression/control plasmid or anti-miR-155 prior to Veh-Exo/Gem-Exo and subsequent gemcitabine treatment, and cell viability was determined by WST-1 assay as described earlier ([@bib7]).

Apoptosis assay
---------------

Cells (1 × 10^6^ per well) were grown in six-well plates overnight under regular culture conditions, treated with CM or EVs or exosomes (12 h) prior to gemcitabine (10 *μ*[M]{.smallcaps}) treatment for 72 h and extent of apoptosis was measured as previously described ([@bib22]).

Measurement of reactive oxygen species
--------------------------------------

*In vitro* reactive oxygen species (ROS) level was measured by using DCFDA by earlier described method ([@bib3]). Briefly, PC cells were incubated with DCFDA in regular growth medium for 30 min at 37 °C, subsequently cells were washed thrice with 1 × PBS and resuspended in 1 × PBS. Fluorescence intensity in cells was determined by fluorescence microscope (Nikon Eclipse TE2000-U, Melville, NY, USA) as well as with flow cytometry on a FACSCanto IIi (BD Biosciences, San Jose, CA, USA).

RNA isolation and quantitative real-time PCR
--------------------------------------------

Total RNA from PC cells (by TRIzol method) and exosomes (using total exosome RNA isolation kit) was isolated and mRNA/miRNA expression analysis was performed using standard quantitative real-time PCR (qRT-PCR) procedures as described earlier ([@bib43]), using specific primer sets ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). GAPDH and U6 served as housekeeping genes for mRNA and miRNA, respectively. To examine the level of mRNA in exosomes, seminested PCR was performed using gene-specific primers ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Thermal cycle conditions used were 94 °C for 5 min followed by 40 cycles at 94 °C for 30 s, 60 °C for 30 s, 72 °C for 30 s and final extension at 72 °C for 7 min. Subsequently, the second round of PCR was performed using the product of first PCR as a template with same PCR parameters with different reverse primers.

SDS-PAGE and immunoblotting
---------------------------

Total protein from PC cells was isolated in NP40 buffer supplemented with protease phosphatase inhibitor cocktail. An additional 2.0% SDS was added to NP40 buffer for protein isolation from EVs. SDS-PAGE, immunoblotting performed and bands visualised as described earlier ([@bib43]). Briefly, membrane immunoblotted with specific antibodies (1 : 1000) against C3b, THBS, ARF6, CD9, CD63, SOD2, CAT and DCK and *β*-actin served as loading control. Horseradish peroxidase-coupled secondary antibodies were used at 1 : 2500 dilutions. Proteins were visualised with the SuperSignal west femto maximum sensitivity substrate kit (Thermo Scientific, Logan, UT, USA) using ChemiDoc Imaging Systems (Bio-Rad).

Dual-luciferase 3′-UTR reporter assay
-------------------------------------

Dual-luciferase 3′-UTR reporter assay was performed to validate whether DCK is a direct target of miR-155 using a target reporter plasmids containing DCK 3′-UTR region as described previously ([@bib43]). As a control, a mutant plasmid (MUT-DCK 3′-UTR) containing mutated miR-155-binding sites in DCK 3′-UTR was generated using Quickchange XL site-directed mutagenesis kit and also used in reported assay.

Statistical analysis
--------------------

All experiments were performed at least three times and data expressed as mean±s.d. Wherever appropriate, the data were subjected to unpaired two-tailed Student\'s *t*-test and *P*\<0.05 was considered statistically significant.

Results
=======

Extracellular vesicles release from gemcitabine-treated PC cells promotes chemoresistance
-----------------------------------------------------------------------------------------

We hypothesised that PC cells, upon treatment with chemotherapy, release some factors in a counter-defence mechanism leading to their acquired chemoresistance. To test this possibility, we treated PC cell lines (MiaPaCa and Colo-357) with vehicle or gemcitabine for 8 h and then cultured them in fresh media for next 48 h. Conditioned media collected from vehicle- (Veh-CM) and gemcitabine-treated (Gem-CM) PC cells were used to pretreat naive culture of PC cells for 12 h, followed by gemcitabine treatment (0--80 *μ*[M]{.smallcaps}) for next 72 h. Subsequent cell viability measurements demonstrated significantly reduced (*P*\<0.01) gemcitabine toxicity in PC cells that had been pretreated with Gem-CM as compared to those pretreated with Veh-CM. Overall increase in IC~50~ values for Gem-CM pretreated MiaPaCa and Colo-357 cells was ∼3.2- and 2.2-fold, respectively, relative to the cells that received Veh-CM pretreatment ([Figure 1A](#fig1){ref-type="fig"}).

We next investigated whether the acquired chemoresistance involved SF or EV fraction of CM. For this, CM was fractionated into SF (Veh-SF/Gem-SF) and EVs (Veh-EVs/Gem-EVs) through ultracentrifugation and these sub-fractions were used to treat PC cells prior to gemcitabine exposure. Data revealed that Gem-SF pretreatment had only minimal (∼1.2-fold) chemoprotective effect in both the PC cell lines against gemcitabine ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}), whereas significantly greater (*P*\<0.01) chemoprotection was provided by Gem-EVs. IC~50~ values for Gem-EVs-treated PC cells were increased ∼3.09-fold (in MiaPaCa) and ∼2.0-fold (in Colo-357) with respect to those pretreated with Veh-EVs ([Figure 1B](#fig1){ref-type="fig"}). This chemoprotection was further confirmed through flow-cytometry-based apoptosis assay. Pancreatic cancer cells treated with Gem-CM prior to gemcitabine (10 *μ*[M]{.smallcaps}) treatment had lower apoptotic indices (17.0% and ∼18.3%) compared to Veh-CM pretreated (39.1% and 38.9%) MiaPaCa and Colo-357 cells, respectively, ([Figure 1C](#fig1){ref-type="fig"}). Similarly, percentage of apoptotic MiaPaCa and Colo-357 cells was decreased (18.4% and 23.3%, respectively) upon pretreatment with Gem-EVs in comparison to those pretreated with Veh-EVs (38.3% and 42.9%, respectively; [Figure 1D](#fig1){ref-type="fig"}). Together, these findings establish a clear role of EVs in acquired chemoresistance of PC.

Exosomes are the main EVs imparting acquired chemoresistance
------------------------------------------------------------

As EVs may represent heterogeneous population of different size and origin ([@bib11]; [@bib32]), we sub-fractionated them into large-, moderate- and small-sized EVs by differential centrifugation as depicted in [Figure 2A](#fig2){ref-type="fig"}. Size distribution of these sub-fractions was measured by dynamic light scattering analysis. Average size of the large, moderate and small EVs was recorded to be \>2000, ∼800 and \<150 nm, respectively ([Figure 2B](#fig2){ref-type="fig"}). Interestingly, the sizes of different EVs sub-fractions from gemcitabine-treated PC cells tended to be towards somewhat higher side as compared to those treated with vehicle only (2918 vs 2426.6 nm (large) 883 vs 846.1 nm (moderate), and 124.8 vs 103.6 nm (small); [Figure 2B](#fig2){ref-type="fig"}). Moreover, protein amount of secreted exosomes from gemcitabine-treated MiaPaCa and Colo-357 cells is also significantly higher ∼1.75- and 1.52-fold, respectively, as compared to vehicle-treated PC cells ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). We next performed immunoblot analysis to investigate the nature of different EV sub-fractions using antibodies against membrane-specific biomarkers. Data revealed that large-, moderate- and small-sized sub-fractions from both Veh- or Gem-EVs were positive for C3b and thrombospondin (apoptotic bodies, ABs), ARF6 (microvesicles, MVs) and CD63 and CD9 (exosomes, Exo) markers, respectively ([Figure 2C](#fig2){ref-type="fig"}).

To examine the specific sub-fraction(s) of EVs mediating acquired chemoresistance, PC cells were pretreated with ABs, MVs and Exo separately, and their effect on gemcitabine cytotoxicity was examined. We observed that Gem-Exo provided significant chemoprotection to PC cells by decreasing gemcitabine sensitivity ([Figure 2D](#fig2){ref-type="fig"}), whereas both Gem-ABs and Gem-MVs failed to provide any protection ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). IC~50~ values of gemcitabine in Gem-Exo-pretreated MiaPaCa and Colo-357 were recorded to be ∼14.5 and 7.7 *μ*[M]{.smallcaps}, respectively, as compared to that from Veh-Exo pretreated cells (∼6.8 and 3.7 *μ*[M]{.smallcaps}, respectively), indicating more than two fold change. We further confirmed these findings by performing apoptosis analysis on Gem-Exo and Veh-Exo pretreated PC cells ([Figure 2E](#fig2){ref-type="fig"}). Together, these data establish exosomes to be major mediators in gemcitabine-induced acquired chemoresistance in PC cells.

Expression of CAT and SOD2 is increased, whereas DCK is downregulated in PC cells exhibiting acquired chemoresistance
---------------------------------------------------------------------------------------------------------------------

Several studies have suggested that genes involved in survival pathways may confer cancer chemoresistance ([@bib46]; [@bib47]). In other reports, a role of enzymes involved in ROS detoxification and drug metabolism has been suggested in cancer chemoresistance ([@bib15]; [@bib30]; [@bib49]; [@bib25]). Therefore, we used a qPCR-based custom array to identify differentially expressed genes in Veh-Exo- and Gem-Exo-pretreated PC cells. We observed that out of several genes tested in our analysis, expression of *CAT* and *SOD2* (both encoding ROS-detoxifying enzymes, CAT and SOD2, respectively) was upregulated in Gem-Exo-pretreated MiaPaCa (1.73- and 1.83-fold, respectively) and Colo-357 (1.49- and 1.63-fold, respectively) cells as compared to that of Veh-Exo-treated cells. However, we recorded a decrease in the expression of *DCK* (encoding DCK, a gemcitabine-metabolising enzyme) by 1.47- and 1.38-fold in Gem-Exo-pretreated MiaPaCa and Colo-357 cells, respectively ([Figure 3A](#fig3){ref-type="fig"}). Differential expression of these genes were further confirmed at protein level by immunoblot assay. Interestingly, we observed a greater fold change for DCK (3.1-fold, MiaPaCa and 2.6-fold, Colo-357) at protein level ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}) relative to that at the transcript level ([Figure 3A](#fig3){ref-type="fig"}). We next examined whether the differential expression of *CAT*, *SOD2* and *DCK* was sustained for the duration of subsequent gemcitabine treatment. Therefore, PC cells were treated with Veh-Exo or Gem-Exo for additional 24, 48 and 72 h followed by gene expression analyses at mRNA ([Figure 3B](#fig3){ref-type="fig"}) and protein ([Figure 3C](#fig3){ref-type="fig"}) levels. Considering primary changes at the transcript levels and established role of exosomes as carriers of RNAs ([@bib4]; [@bib32]), we examined relative levels of *CAT*, *SOD2* and *DCK* in Gem-Exo and Veh-Exo by seminested PCR. As expected, we observed increased levels of *CAT* and *SOD2* transcripts in Gem-Exo as compared to that in Veh-Exo; however, no *DCK* transcript was detected in any of the exosomal fractions ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}), suggesting an alternative mechanism for its regulation. To further support our findings on possible exosome-mediated lateral transfer of *CAT* and *SOD2* transcripts, we analysed their expression in Gem-treated PC cells at 8, 8+24 and 8+48 h. The data show that expression of *SOD2* and *CAT* in PC cells is increased within 8 h of gemcitabine treatment and continues to increase with time ([Supplementary Figure 6](#sup1){ref-type="supplementary-material"}). It is; however, likely that *SOD2* and *CAT* upregulation in Gem-Exo-treated PC cells may occur through other, not yet identified, mechanisms as well.

Reduction in ROS levels by CAT and SOD2 is partly responsible for acquired chemoresistance of PC cells
------------------------------------------------------------------------------------------------------

As CAT and SOD2 are ROS-detoxifying enzymes, we examined the levels of ROS in Veh-Exo- and Gem-Exo-treated PC cells. A significant decrease (*P*\<0.01) in ROS levels was observed in Gem-Exo-treated PC cells as compared to that in Veh-Exo-treated cells ([Figure 4A and B](#fig4){ref-type="fig"}). More importantly, Gem-Exo was also effective in reducing gemcitabine-induced increase in ROS levels in PC cells, although relatively less effective in comparison with NAC ([Figure 4C](#fig4){ref-type="fig"}). In contrast, Gem-Exo provided greater chemoprotection as compared to NAC pretreatment ([Figure 4D](#fig4){ref-type="fig"}), suggesting only a partial role of ROS detoxification in Gem-Exo-induced acquired chemoresistance. To directly establish the participation of CAT and SOD2 in Gem-Exo-mediated ROS reduction and consequent chemoprotection, we pretreated MiaPaCa cells with specific inhibitors of CAT (AT) and SOD2 (DDC) prior to Gem-Exo treatment either alone or in combination, and their effect on ROS levels and cell viability was examined. As expected, pretreatment of PC cells with AT and DDC abrogated Gem-Exo-mediated decrease in ROS levels with their combination being more effective ([Figure 4E](#fig4){ref-type="fig"}). However, subsequent cell viability analyses of treated PC cells demonstrated that Gem-Exo-induced acquired chemoresistance was partly abrogated upon pretreatment with CAT and SOD2 inhibitors ([Figure 4F](#fig4){ref-type="fig"}). Together, these data suggest a partial role of CAT and SOD2 in Gem-Exo-induced chemoresistance of PC cells via causing a decrease in total cellular ROS levels.

miR-155 inhibits *DCK* expression in Gem-Exo-treated PC cells
-------------------------------------------------------------

Having observed only partial role of CAT and SOD2 in exosome-mediated chemoresistance, we focused our attention on *DCK*, whose expression was decreased in Gem-Exo-treated PC cells. We first investigated the mechanism that caused *DCK* downregulation in Gem-Exo-treated PC cells as no DCK transcript was detected in exosomes from either vehicle or gemcitabine-treated PC cells ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). Hence, we performed *in silico* analysis using the algorithms TargetScan (<http://www.targetscan.org>) and miRanda (<http://www.microrna.org>) to shortlist *DCK*-targeting miRNAs. Our analysis identified eight putative *DCK*-targeting miRNAs (data not shown), whose presence was examined in Veh-Exo and Gem-Exo- by qRT-PCR. miR-155 was found to be the most differentially expressed miRNA in Gem-Exo *vs* Veh-Exo exhibiting ∼9.0- and 6.5-fold higher levels in the former derived from MiaPaCa and Colo-357 cells, respectively ([Figure 5A](#fig5){ref-type="fig"}). Accordingly, we also observed enhanced levels of miR-155 (∼3.2- and 2.7-fold) in Gem-Exo-treated cells as compared to Veh-Exo-treated MiaPaCa and Colo-357 cells, respectively ([Figure 5B](#fig5){ref-type="fig"}). We next validated whether functional suppression of miR-155 by specific anti-miRs in Gem-Exo-treated cells would alter *DCK* expression. The data revealed that *DCK* expression was restored by anti-miR-155 treatment in Gem-Exo-treated PC cells ([Figure 5C](#fig5){ref-type="fig"}). To confirm direct targeting of DCK 3′-UTR by miR-155, we next performed luciferase-based 3′-UTR reporter assay using plasmids containing wild-type (WT) or mutated (MUT) 3′-UTR regions of *DKC* ([Figure 5D](#fig5){ref-type="fig"}). We observed \>75% decrease in luciferase activity in Gem-Exo-treated PC cells that were transfected with WT-3′-UTR of *DCK* containing reporter plasmid, whereas those transfected with MUT-3′-UTR of DCK did not show any response to the suppressor activity of Gem-Exo ([Figure 5E](#fig5){ref-type="fig"}). These data provide strong evidence that Gem-Exo-mediated delivery of miR-155 causes *DCK* downregulation in PC cells by directly targeting its 3′-UTR.

Functional suppression of miR-155 or restoration of *DCK* expression abrogates exosome-mediated acquired chemoresistance in PC cells
------------------------------------------------------------------------------------------------------------------------------------

To confirm the involvement of miR-155 in Gem-Exo-mediated chemoresistance, we transfected PC cells with control anti-miR or anti-miR-155 for 12 h followed by 12 h treatment with Veh-Exo or Gem-Exo. Thereafter, its effects on suppression of miR-155 activity and cell viability in presence of gemcitabine were examined by luciferase-based 3′-UTR reporter and WST-1 assays, respectively. Decreased luciferase activity in Gem-Exo-treated PC cells upon transfection of anti-miR-155 was observed as compared to that in cells transfected with control anti-miR, suggesting the functional inhibition of miR-155 through anti-miR-155 ([Figure 6A](#fig6){ref-type="fig"}). Moreover, we observed that anti-miR-155-treated PC cells became more sensitive to gemcitabine as compared to those treated with non-target (NT) sequence control ([Figure 6B](#fig6){ref-type="fig"}). Further, we tested the effect of direct restoration of DCK in Gem-Exo-induced acquired chemoresistance. For this, we transfected PC cells with *DCK* overexpression plasmid, which contains the entire coding sequence of *DCK*, but lacks the 3′-UTR, prior to Gem-Exo treatment. Expression of *DCK* was examined by immunoblot analysis. We observed that *DCK* overexpression plasmid was able to restore *DCK* expression in Gem-Exo-treated PC cells ([Figure 6C](#fig6){ref-type="fig"}). Next, the effect of DCK restoration on the viability of Gem-Exo-treated PC cells in the presence or absence of gemcitabine was determined. A significant abrogation of Gem-Exo-induced chemoprotection in MiaPaCa and Colo-357 cells was reported upon forced *DCK* overexpression as compared to cells transfected with control plasmid ([Figure 6D](#fig6){ref-type="fig"}). In a converse approach, expression of *DCK* was silenced in PC cells treated with Veh-Exo through transient transfection of *DCK-*targeting specific siRNAs pool and effect on gemcitabine-induced cytotoxicity was measured by WST-1 assay. *DCK* siRNAs efficiently silenced *DCK* expression by 24 h, an effect that sustained at least up to 72 h post transfection ([Supplementary Figure 7A](#sup1){ref-type="supplementary-material"}). As expected, silencing of *DCK* enhanced the resistance to gemcitabine toxicity in Veh-Exo-treated PC cells ([Supplementary Figure 7B](#sup1){ref-type="supplementary-material"}). Collectively, our findings suggest that Gem-Exo-mediated downregulation of gemcitabine metabolism enzyme, DCK, provides survival advantage to the gemcitabine-treated PC cells.

Discussion
==========

Pancreatic cancer is largely an untreatable disease due to the presence of several intrinsic or acquired chemoresistance mechanisms ([@bib28]; [@bib21]) that still remain to be properly understood. This study made an effort to characterise one such acquired chemoresistance mechanism that could underlie, in part, for the poor therapeutic efficacy of gemcitabine as a single agent or in combination. We hypothesised that upon encountering chemotherapeutic insult, pancreatic tumour cells may release factors that would enable them to fight it or any subsequent insults more effectively. Our findings from this study provide us strong support for this hypothesis and establish exosomes to be important and novel mediators in the process of acquired chemoresistance ([Figure 7](#fig7){ref-type="fig"}).

Several mechanisms have been proposed and/or experimentally validated to be operational in pancreatic tumour as well as its host to cause its unusual chemoresistance. One mechanism that gained extensive attention lately is the unique histoarchitecture of pancreatic tumours that provides indirect chemoprotection ([@bib31]). It was shown that excessive fibrosis in the surrounding of tumour cells, referred to as desmoplasia, acted as a physical barrier for drug delivery and its targeting significantly improved therapeutic outcome in a preclinical model ([@bib31]). However, this approach failed in clinical trial further underscoring the complexity of underlying molecular mechanisms of PC chemoresistance ([@bib1]). Recently, we and others have focused on additional mechanisms that involve cell-to-cell and/or cell-to-matrix interactions through release of soluble growth factors, direct intercellular interactions and generation of growth favourable niches within tumour microenvironment ([@bib40], 2012; [@bib9]; [@bib8]). We demonstrated that stromal-derived chemokine, CXCL12, conferred gemcitabine resistance in PC cells ([@bib40]). Moreover, we suggested that the activation of this signalling pathway could also promote desmoplasia through bi-directional tumour--stromal interactions ([@bib39]). Our other findings not only supported the importance of this chemokine pathway, but also indicated its role in promotion of tumour spread as an unintended effect of chemotherapy ([@bib3]). This notion was further supported by our observation of chemotherapy-induced pro-angiogenic signalling that could potentially facilitate cancer cell\'s escape to new chemoprotective and growth-permissive niches ([@bib22]). In the same line, our present findings add another novel mode for acquired chemoresistance in PC that could be of significance for many other cancer types as well.

Exosomes are a novel class of cellular entity that has gained enormous momentum lately as facilitators of tumour growth and metastasis ([@bib4]; [@bib12]; [@bib35]; [@bib41]). It was recently reported that exosomes assist in the process of pre-metastatic niche formation for evolving pancreatic tumours by travelling to distant locations ([@bib12]). Another study from the same group established exosomes as important mediators in organ-specific homing of tumour cells ([@bib18]). The data from current study suggest that exosomes may confer chemoresistance to themselves or neighbouring PC cells via intercellular transfer of involved molecular factors. Specifically, our data suggested that exosomes caused direct transfer of *SOD2* and *CAT* transcripts that encode for ROS-detoxifying enzymes. Moreover, we observed indirect downregulation of gemcitabine-metabolising enzyme, DCK, in pancreatic tumour cells via transfer of its targeting miRNA (miR-155). Exosomal transfer of proteins, RNA, DNA and miRNAs from donor to the recipient cells have been reported in multiple studies and suggested to induce phenotypic and/or genotypic changes in the receiving cells ([@bib16]; [@bib10]). By this virtue, exosomes may impact several aspects of tumour development and therapy, and may have shorter- as well as longer-term implications, some of which are now starting to be recognised.

Generation of ROS by chemotherapeutic drugs is suggested to be one important mechanism for its cytotoxic efficacy ([@bib44]; [@bib14]). Tumour cells try to counter-balance this abrupt increase in ROS by altering the expression of ROS-detoxifying enzymes. Both CAT and SOD2, shown to be partly implicated in acquired resistance of PC in our study, have been suggested to promote chemoresistance in cancer ([@bib13]; [@bib48]). Similarly, in other studies a role of gemcitabine-metabolising enzymes has been reported to underlie chemoresistant nature of PC cells ([@bib15]; [@bib2]; [@bib8]). Specifically, human equilibrative nucleoside transporter-1 and DCK have been shown to induce gemcitabine resistance in cancer cells by limiting its uptake and conversion to active metabolite form, respectively ([@bib30]; [@bib29]). In this regard, our finding of exosome-mediated suppression of *DCK* is of great relevance. More importantly, it also point out towards a novel mechanism of *DCK* regulation in PC that occurs through exosome-mediated transfer of its targeting miRNA. MiRNAs are small non-coding regulatory RNAs that negatively modulate gene expression via binding to 3′-UTR of their target genes ([@bib6], [@bib5]). As miRNA binding to its target 3′-UTR does not have to be perfect, a single miRNA can regulate the expression of multiple genes ([@bib42]). Therefore, our observation on exosomal transfer of miR-155 may have additional consequences that yet need to be determined. Recently, miR-155 was shown to be a major factor in PC survival, invasion and migration ([@bib17]), which further supports our notion of its broader pathological implications.

In summary, we have established a novel mechanism of acquired chemoresistance in PC, which involves exosomes as carriers of mRNAs and miRNA having a role in ROS detoxification and gemcitabine metabolism. Specifically, we have identified *CAT*, *SOD2* and *DCK* as important genes involved in exosome-mediated PC chemoresistance. Moreover, our findings have revealed miR-155 to be a novel regulator of *DCK* expression in PC. Together, these findings not only define a novel role of exosomes, but also unravel a novel molecular basis for unusual chemoresistance of PC.
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![**Conditioned media and its vesicular fraction from gemcitabine-treated pancreatic cancer cells provide chemoresistance.**PC cells were pretreated with (**A**) conditioned media from vehicle-(Veh-CM) or gemcitabine-treated (Gem-CM) PC cells, or (**B**) their extracellular vesicular fractions (Veh-EVs and Gem-EVs) for 12 h. Subsequently, cells were exposed with gemcitabine (0--80 *μ*[M]{.smallcaps}) and viability measured by WST-1 assay after 72 h. Data shown as mean±s.d.; (*n*=3) \**P*\<0.05. (**C**, **D**) Cells were treated with (**C**) Veh-CM or Gem-CM, and (**D**) Veh-EVs or Gem-EVs for 12 h prior to gemcitabine (10 *μ*[M]{.smallcaps}) treatment for 72 h and number of apoptotic cells were determined.](bjc201718f1){#fig1}

![**Exosomal fraction is mainly responsible for acquired chemoresistance conferred by extracellular vesicles.**(**A**) EVs were sub-fractionated by differential centrifugation. (**B**) Sizes of the different EVs were determined by dynamic light scattering. (**C**) Expression of specific markers for apoptotic bodies (C3b and THBS), microvesicles (ARF6) and exosomes (CD63 and CD9) by immunoblotting. (**D**) Cells were treated for 12 h with Veh-Exo or Gem-Exo prior to the gemcitabine (0--80 *μ*[M]{.smallcaps}) treatment and viability was determined by WST-1 assay after 72 h. Data expressed as mean±s.d.; (*n*=3) \**P*\<0.05. (**E**) Cells were pretreated with Veh-Exo or Gem-Exo for 12 h followed by gemcitabine (10 *μ*[M]{.smallcaps}) treatment for 72 h. Thereafter, apoptotic indices were measured by flow cytometry.](bjc201718f2){#fig2}

![**Gem-Exo modulates the expression of catalase (CAT), superoxide dismutase 2 (SOD2) and deoxycytidine kinase (DCK) in PC cells.**(**A**) PC cells were treated with Veh-Exo or Gem-Exo for 12 h and expression of genes involved in cell survival, ROS detoxification and gemcitabine metabolism was analysed. Three genes (*SOD2*, *CAT* and *DCK*) exhibited differential expression in both cell lines, which were confirmed at both mRNA and protein levels ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). (**B**, **C**) To examine whether the changes in gene expression sustained for the duration of subsequent gemcitabine treatment, Veh-Exo- or Gem-Exo-pretreated cells were grown for additional 24, 48 or 72 h and expression of *CAT*, *SOD2* and *DCK* was examined at (**B**) mRNA and (**C**) protein levels. GAPDH (for mRNA) and *β*-actin (for protein) served as internal controls. Bars represent mean±s.d.; *n*=3. \**P*\<0.05.](bjc201718f3){#fig3}

![**Decrease in basal and gemcitabine-induced reactive oxygen species levels by increased activity of catalase and superoxide dismutase 2 (SOD2) is partly responsible for acquired chemoresistance of pancreatic cancer cells.**To examine whether enhanced expression of CAT and SOD2 resulted in decreased ROS levels, we treated MiaPaCa cells, with Veh-Exo or Gem-Exo for 12 and 24 h. Cells were then incubated with DCFDA (20 *μ*[M]{.smallcaps}) for 30 min, washed and analysed for ROS level by (**A**) fluorescence microscope and (**B**) flow cytometry. Representative images are shown from three independent experiments. (**C**, **D**) PC cells were pretreated with Veh-Exo or Gem-Exo (for 12 h) or with an effective ROS scavenger, NAC (10 m[M;]{.smallcaps} for 1 h) followed by gemcitabine treatment (10 *μ*[M]{.smallcaps}) alone or in combinations. Effect on (**C**) ROS level (after 24 h) and (**D**) cell viability (after 72 h) were determined through flow cytometry and WST-1 assays, respectively. (**E**) In additional experiments, cells were treated with inhibitors of catalase (AT; 10 *μ*[M]{.smallcaps}) or SOD2 (DDC; 1.0 *μ*[M]{.smallcaps}) alone or in combinations 1 h prior to Veh-Exo or Gem-Exo treatment, and intracellular ROS level measured. (**F**) Cells pretreated with CAT and SOD2 inhibitors were examined for their role in abrogating exosome-induced gemcitabine resistance by WST-1 assay. Data are presented as mean±s.d.; *n*=3. \**P*\<0.05.](bjc201718f4){#fig4}

![**Downregulation of DCK expression in pancreatic cancer cells occurs through exosome-mediated delivery of miR-155.**(**A**) Exosomes (Veh-Exo/Gem-Exo) were isolated, and expression of miR-155 examined through qRT-PCR. U6 was used as internal control. (**B**) Expression of miR-155 was also examined in Veh-Exo or Gem-Exo-treated PC cells through qRT-PCR. (**C**) PC cells were pretreated with control or miR-155-targeting miRs for 12 h followed by Veh-Exo/Gem-Exo treatment for 12 h. Thereafter, total protein was isolated and expression of DCK was measured by immunoblotting. (**D**) Schematic representation of firefly luciferase reporter construct containing DCK 3′-UTR with either wild-type (WT) or mutant (MUT) miR-155 target site. (**E**) PC cells were transiently co-transfected with reporter plasmids (200 ng) 24 h prior to Veh-Exo or Gem-Exo treatment for additional 24 h. Subsequently, protein lysates were made and luciferase (Firefly; test and Renilla, transfection efficiency control) activity assessed using dual-luciferase assay system. Data presented as normalised fold change in luciferase activity (mean±s.d.; *n*=3, \**P*⩽0.05).](bjc201718f5){#fig5}

![**Restoration of DCK expression abrogates Gem-Exo-induced acquired chemoresistance in PC cells.**(**A**) PC cells were transiently transfected with wild-type reporter plasmids 24 h prior to control or anti-miR-155 transfection. After 12 h, cells were treated with Veh-Exo or Gem-Exo for additional 24 h and luciferase activity assessed. Data presented as mean±s.d.; *n*=3. (**B**) PC cells were pretreated with control anti-miR or anti-miR-155 for 12 h followed by 12 h treatment with Veh-Exo or Gem-Exo. Thereafter, cells were exposed to gemcitabine (10 *μ*[M]{.smallcaps}) for additional 72 h, and viability was measured through WST-1 assay. Data represent as mean±s.d.; *n*=3. \**P*\<0.05. (**C**, **D**) PC cells were transiently transfected with control or *DCK* overexpression plasmid and treated with Gem-Exo for 12 h. Post treatment, (**C**) protein was collected and *DCK* expression was determined through immunoblotting. *β*-Actin served as loading control. (**D**) Cells were further treated with gemcitabine (10 *μ*[M]{.smallcaps}) and viability measured by WST-1 after 72 h.](bjc201718f6){#fig6}

![**Mechanistic representation of exosomes-mediated acquired chemoresistance in PC.**Exosomes from gemcitabine-treated PC cells deliver *CAT* and *SOD2* transcripts leading to enhanced expression of reactive oxygen species (ROS)-detoxifying enzymes, catalase (CAT) and superoxide dismutase 2 (SOD2), respectively. Reduction in basal as well as gemcitabine-induced ROS levels by CAT and SOD2 protects PC cells from ROS-induced cell death. On the other hand, miR-155 delivered via exosomes downregulates the expression of *DCK*, which encodes for gemcitabine-metabolising enzyme, deoxycytidine kinase (DCK). Deoxycytidine kinase is required for phosphorylation of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine, dFdC) into gemcitabine-monophosphate (dFdCMP), which is then converted to active metabolite form of gemcitabine (gemcitabine-triphosphate (dFdCTP)). dFdCTP incorporates into DNA, halts the replication process, and ultimately results in apoptotic cell death.](bjc201718f7){#fig7}
